How novel therapies target atherogenic Lp(a) particle

PHILADELPHIA — With several lipoprotein(a) therapies nearing market availability, physicians at the Heart in Diabetes CME Conference discussed the underlying mechanisms these therapies used to prevent atherosclerotic CVD.Healio | Cardiology Today Editorial Board Member Steven E. Nissen, MD, MACC, the Lewis and Patricia Dickey Chair in Cardiovascular Medicine at Cleveland Clinic, reviewed